Dr Reddys sign agreement to acquire Dowpharma

Dr. Reddy’s Laboratories recently announced that it has entered into a definitive agreement with the Dow Chemical Company to acquire a portion of Dowpharma Small Molecules business associated with its UK sites in Mirfield and Cambridge. The financial terms and conditions of the transaction are not being disclosed at this point in time.
The acquisition will include the relevant business, customer contracts, associated products, process technology, intellectual property, trademarks as well as the transfer of the facilities at Mirfield and Cambridge in the UK. The two sites and the business employ around 80 people. Dr. Reddy’s will also have a non-exclusive license to Dow’s Pfenex Expression Technology™ for biocatalysis development.
Satish Reddy, Managing Director & Chief Operating Officer, Dr. Reddy’s Laboratories, said, “The proprietary chiral and biocatalysis technology at the Cambridge site and the scale up capability in the Mirfield site will add significant value to the company. This acquisition will also bring strengths in industrial synthesis of complex prostaglandins and carbohydrate chemistry.”